• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过树突状细胞上免疫检查点 CD40/CD40L 的激活诱导针对胆管细胞、胰腺和结直肠肿瘤细胞的细胞毒性效应细胞。

Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.

机构信息

Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53105, Bonn, Germany.

Department of Visceral Surgery, University Hospital Bonn, Bonn, Germany.

出版信息

Cancer Immunol Immunother. 2021 May;70(5):1451-1464. doi: 10.1007/s00262-020-02746-x. Epub 2020 Nov 12.

DOI:10.1007/s00262-020-02746-x
PMID:33180184
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8053193/
Abstract

INTRODUCTION

Gastrointestinal (GI) malignancies, such as cholangiocarcinoma, pancreatic carcinoma, and metastatic colorectal carcinoma, have a poor prognosis and effective therapeutic approaches are still challenging. Checkpoint inhibition with PD-1 or PDL-1 antibodies revealed promising results in different tumor entities; however, only few patients with GI tumors can potentially benefit from PD1/PDL1 inhibiting immunotherapy. Further immunotherapeutic strategies for GI malignancies are urgently needed. The aim of this study was to demonstrate that in vitro activation of the immune checkpoint CD40/CD40L can improve DC action towards bile duct, pancreas, and colorectal carcinoma.

METHODS

Human DC were isolated from buffy coats from healthy donors, pulsed with tumor lysates and then transduced with adenoviruses encoding human CD40L (Ad-hCD40L). Using transwell assays, the effects of (m)CD40L on DC immunoactivation compared to (s)CD40L were analyzed. Surface marker and cytokine/chemokine expression were measured by flow cytometry, ELISA and cytokine arrays. Capacity of Ad-hCD40L-transduced DC to induce tumor-specific effector cells was tested using MTT proliferation assay and cytotoxicity assays. Apoptosis induction on tumor cells after culturing with supernatants of Ad-hCD40L-transduced DC was analyzed by flow cytometry.

RESULTS

Ad-hCD40L transduction induced a high expression of (s)CD40L and (m)CD40L on DC and seemed to induce a strong cellular CD40/CD40L interaction among DC, leading to the formation of cell aggregates. Due to the CD40/CD40L interaction, a significant upregulation of DC maturation markers and a Th1-shift on cytokines/chemokines in the supernatant of DC were achieved. Interestingly, a pure Th1-shift was only achieved, when a cellular CD40/CD40L interaction among DC took place. (s)CD40L induced almost no upregulation of maturation markers and rather resulted in a Th2-cytokine expression, such as IL-10. Correspondingly, (m)CD40L-expressing DC led to significant proliferation and stimulation of tumor-specific effector cells with increased cytotoxicity towards pancreatic, bile duct and colorectal tumor cells. Supernatants of Ad-hCD40L-transduced DC could also induce apoptosis in the different tumor cells in vitro.

CONCLUSION

Stimulation of the immune checkpoint CD40L/CD40 by endogenous expression of (m)CD40L provokes a cellular interaction, which increases the immunomodulatory capacity of DC. A Th1 cytokine/chemokine expression is induced, leading to a significant proliferation and enabling cytotoxicity of effector cells towards human bile duct, pancreatic and colorectal tumor cells. The present data point to the promising approach for DC-based immunotherapy of gastrointestinal malignances by activating the CD40/CD40L immune checkpoint.

摘要

简介

胃肠道(GI)恶性肿瘤,如胆管癌、胰腺癌和转移性结直肠癌,预后较差,有效的治疗方法仍然具有挑战性。PD-1 或 PDL-1 抗体的检查点抑制在不同的肿瘤实体中显示出了有希望的结果;然而,只有少数胃肠道肿瘤患者可能受益于 PD1/PDL1 抑制免疫疗法。迫切需要进一步的胃肠道恶性肿瘤免疫治疗策略。本研究旨在证明体外激活免疫检查点 CD40/CD40L 可以改善树突状细胞(DC)对胆管、胰腺和结直肠癌细胞的作用。

方法

从健康供者的白细胞中分离人 DC,用肿瘤裂解物脉冲,然后用编码人 CD40L 的腺病毒(Ad-hCD40L)转导。通过 Transwell 测定分析(m)CD40L 与(s)CD40L 相比对 DC 免疫激活的影响。通过流式细胞术、ELISA 和细胞因子数组测定表面标志物和细胞因子/趋化因子的表达。使用 MTT 增殖测定和细胞毒性测定测试 Ad-hCD40L 转导的 DC 诱导肿瘤特异性效应细胞的能力。通过流式细胞术分析培养上清液中转导的 Ad-hCD40L 的 DC 对肿瘤细胞的凋亡诱导。

结果

Ad-hCD40L 转导诱导 DC 高水平表达(s)CD40L 和(m)CD40L,并似乎诱导 DC 之间强烈的细胞 CD40/CD40L 相互作用,导致细胞聚集的形成。由于 CD40/CD40L 的相互作用,在 DC 的上清液中实现了 DC 成熟标志物的显著上调和 Th1 向细胞因子/趋化因子的转移。有趣的是,只有当 DC 之间发生细胞 CD40/CD40L 相互作用时,才会实现纯 Th1 转移。(s)CD40L 诱导的成熟标志物上调几乎没有,而导致 Th2 细胞因子的表达,如 IL-10。相应地,表达(m)CD40L 的 DC 导致对胰腺、胆管和结直肠肿瘤细胞的显著增殖和刺激肿瘤特异性效应细胞,增加对这些肿瘤细胞的细胞毒性。Ad-hCD40L 转导的 DC 上清液也可以在体外诱导不同肿瘤细胞的凋亡。

结论

内源性表达(m)CD40L 刺激免疫检查点 CD40L/CD40 引发细胞相互作用,从而增加 DC 的免疫调节能力。诱导 Th1 细胞因子/趋化因子的表达,导致效应细胞对人胆管、胰腺和结直肠肿瘤细胞的显著增殖和细胞毒性。本数据表明,通过激活 CD40/CD40L 免疫检查点,为胃肠道恶性肿瘤的基于 DC 的免疫治疗提供了有希望的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce77/10991955/24626b96d263/262_2020_2746_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce77/10991955/b512063a1cb1/262_2020_2746_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce77/10991955/f8936c963209/262_2020_2746_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce77/10991955/f92c3ba8842a/262_2020_2746_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce77/10991955/b0e789eebbd8/262_2020_2746_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce77/10991955/94c5dc8490c3/262_2020_2746_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce77/10991955/98b3b28a2d53/262_2020_2746_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce77/10991955/24626b96d263/262_2020_2746_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce77/10991955/b512063a1cb1/262_2020_2746_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce77/10991955/f8936c963209/262_2020_2746_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce77/10991955/f92c3ba8842a/262_2020_2746_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce77/10991955/b0e789eebbd8/262_2020_2746_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce77/10991955/94c5dc8490c3/262_2020_2746_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce77/10991955/98b3b28a2d53/262_2020_2746_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce77/10991955/24626b96d263/262_2020_2746_Fig7_HTML.jpg

相似文献

1
Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.通过树突状细胞上免疫检查点 CD40/CD40L 的激活诱导针对胆管细胞、胰腺和结直肠肿瘤细胞的细胞毒性效应细胞。
Cancer Immunol Immunother. 2021 May;70(5):1451-1464. doi: 10.1007/s00262-020-02746-x. Epub 2020 Nov 12.
2
Immune Check Point CD40-CD40L Activates Dendritic and Effector Cells Against Human Renal Carcinoma Cells.免疫检查点 CD40-CD40L 激活树突状细胞和效应细胞对抗人肾癌细胞。
Anticancer Res. 2019 Sep;39(9):4643-4652. doi: 10.21873/anticanres.13645.
3
Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy.腺病毒载体介导的多发性骨髓瘤细胞表达人CD40配体(hCD40L)。一种免疫治疗模型。
Exp Hematol. 2001 Aug;29(8):952-61. doi: 10.1016/s0301-472x(01)00668-3.
4
CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.表达CD40配体的树突状细胞通过在体内激活先天性和获得性免疫来诱导肝细胞癌消退。
Hepatology. 2008 Jul;48(1):157-68. doi: 10.1002/hep.22296.
5
Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.通过腺病毒介导的hCD40L基因与γ干扰素共转染,生成同时分泌白细胞介素-12并具有迁移能力的人树突状细胞。
J Immunother. 2009 Jun;32(5):524-38. doi: 10.1097/CJI.0b013e3181a28422.
6
CD40 signalling induces IL-10-producing, tolerogenic dendritic cells.CD40 信号诱导产生 IL-10 分泌的、具有免疫耐受原性的树突状细胞。
Exp Dermatol. 2010 Jan;19(1):44-53. doi: 10.1111/j.1600-0625.2009.00975.x. Epub 2009 Nov 2.
7
Concurrent delivery of tumor antigens and activation signals to dendritic cells by irradiated CD40 ligand-transfected tumor cells resulted in efficient activation of specific CD8+ T cells.经辐照的转染了CD40配体的肿瘤细胞将肿瘤抗原和激活信号同时传递给树突状细胞,从而有效激活了特异性CD8⁺T细胞。
Cancer Gene Ther. 2004 Feb;11(2):135-47. doi: 10.1038/sj.cgt.7700663.
8
Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells.将CD40配体基因转移至人树突状细胞可诱导自然杀伤细胞介导的针对人癌细胞的抗肿瘤效应。
Int J Cancer. 2007 Apr 1;120(7):1491-8. doi: 10.1002/ijc.22518.
9
Enhanced protective immunity derived from dendritic cells with phagocytosis of CD40 ligand transgene-engineered apoptotic tumor cells via increased dendritic cell maturation.通过增强树突状细胞成熟,源自树突状细胞吞噬CD40配体转基因工程化凋亡肿瘤细胞的增强保护性免疫。
Tumori. 2015 Nov-Dec;101(6):637-43. doi: 10.5301/tj.5000297. Epub 2015 May 15.
10
Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses.树突状细胞产生白细胞介素-12。CD40-CD40L相互作用在Th1型T细胞应答中的作用。
Ann N Y Acad Sci. 1996 Oct 31;795:116-26. doi: 10.1111/j.1749-6632.1996.tb52660.x.

引用本文的文献

1
Unleashing the therapeutic potential of tumor-draining lymph nodes: spotlight on bladder cancer.释放肿瘤引流淋巴结的治疗潜力:聚焦膀胱癌
J Transl Med. 2025 Apr 29;23(1):489. doi: 10.1186/s12967-024-05864-7.
2
Infiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints.胆管癌中的浸润性T淋巴细胞与肿瘤微环境:免疫异质性、细胞间通讯、免疫检查点
Front Immunol. 2025 Jan 8;15:1482291. doi: 10.3389/fimmu.2024.1482291. eCollection 2024.
3
Spatial heterogeneity of the hepatocellular carcinoma microenvironment determines the efficacy of immunotherapy.

本文引用的文献

1
Dendritic cell subsets as vectors and targets for improved cancer therapy.树突状细胞亚群作为载体和靶点用于改善癌症治疗。
Curr Top Microbiol Immunol. 2011;344:173-92. doi: 10.1007/82_2010_48.
肝细胞癌微环境的空间异质性决定免疫治疗的疗效。
Discov Oncol. 2025 Jan 7;16(1):15. doi: 10.1007/s12672-025-01747-5.
4
Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer.聚焦免疫细胞:胆管癌免疫治疗的最新进展
Cancer Manag Res. 2024 Jul 29;16:941-963. doi: 10.2147/CMAR.S474348. eCollection 2024.
5
Ginsenosides: an immunomodulator for the treatment of colorectal cancer.人参皂苷:一种用于治疗结直肠癌的免疫调节剂。
Front Pharmacol. 2024 Jun 12;15:1408993. doi: 10.3389/fphar.2024.1408993. eCollection 2024.
6
Tumor microenvironment characteristics and prognostic role of mA modification in lung squamous cell carcinoma.肺鳞状细胞癌中 mA 修饰的肿瘤微环境特征及预后作用
Heliyon. 2024 Feb 28;10(5):e26851. doi: 10.1016/j.heliyon.2024.e26851. eCollection 2024 Mar 15.
7
Reduced Relapse-Free Survival in Colorectal Cancer Patients with Elevated Soluble CD40 Ligand Levels Improved by Vitamin D Supplementation.可溶性 CD40 配体水平升高的结直肠癌患者缓解后生存时间缩短,维生素 D 补充可改善这一现象。
Nutrients. 2023 Oct 13;15(20):4361. doi: 10.3390/nu15204361.
8
Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).肿瘤免疫微环境与胆管癌的当前免疫治疗(综述)。
Int J Oncol. 2023 Dec;63(6). doi: 10.3892/ijo.2023.5585. Epub 2023 Oct 27.
9
Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB.在 IMGT/mAb-DB 中整合的肿瘤学中单克隆抗体的作用机制。
Front Immunol. 2023 May 5;14:1129323. doi: 10.3389/fimmu.2023.1129323. eCollection 2023.
10
Immunobiology of cholangiocarcinoma.胆管癌的免疫生物学。
J Hepatol. 2023 Sep;79(3):867-875. doi: 10.1016/j.jhep.2023.05.010. Epub 2023 May 16.